title: Activity of cathelicidin peptides against Chlamydia spp.
abstract: The in vitro activity of six cathelicidin peptides against 25 strains of Chlamydia was investigated. SMAP-29 proved to be the most active peptide, reducing the inclusion numbers of all 10 strains of Chlamydia trachomatis tested by > or =50% at 10 microg/ml. This peptide was also active against C. pneumoniae and C. felis.
authors.affiliation: Sezione di Microbiologia, DMCSS, Policlinico S.Orsola, Università di Bologna, Via Massarenti 9, 40138 Bologna, Italy.
authors.forename: Manuela
authors.initials: M
authors.lastname: Donati
authors.forename: Korinne
authors.initials: K
authors.lastname: Di Leo
authors.forename: Monica
authors.initials: M
authors.lastname: Benincasa
authors.forename: Francesca
authors.initials: F
authors.lastname: Cavrini
authors.forename: Silvia
authors.initials: S
authors.lastname: Accardo
authors.forename: Alessandra
authors.initials: A
authors.lastname: Moroni
authors.forename: Renato
authors.initials: R
authors.lastname: Gennaro
authors.forename: Roberto
authors.initials: R
authors.lastname: Cevenini
mesh_terms: D023181:Antimicrobial Cationic Peptides / Q000494:pharmacology*; D001798:Blood Proteins / Q000494:pharmacology*; D054804:Cathelicidins; D002689:Chlamydia / Q000187:drug effects*; D002692:Chlamydia trachomatis / Q000187:drug effects; D016993:Chlamydophila pneumoniae / Q000187:drug effects; D010456:Peptides, Cyclic / Q000494:pharmacology*; D011506:Proteins / Q000494:pharmacology*
chemical_list: D023181:Antimicrobial Cationic Peptides; C102359:BMAP-27; C102360:BMAP-28; D001798:Blood Proteins; D054804:Cathelicidins; D010456:Peptides, Cyclic; D011506:Proteins; C403305:SMAP29 protein, Ovis aries; C094880:protegrin-1; C056454:bactenecin
references.citation: Infect Immun. 1996 Nov;64(11):4863-6
references.pmid: 8890254
references.citation: Infect Immun. 1996 Mar;64(3):709-13
references.pmid: 8641770
references.citation: Emerg Infect Dis. 1996 Oct-Dec;2(4):307-19
references.pmid: 8969247
references.citation: Antimicrob Agents Chemother. 1997 Aug;41(8):1738-42
references.pmid: 9257752
references.citation: Semin Hematol. 1997 Oct;34(4):343-54
references.pmid: 9347585
references.citation: Antimicrob Agents Chemother. 1998 Sep;42(9):2206-14
references.pmid: 9736536
references.citation: FEBS Lett. 1999 Dec 10;463(1-2):58-62
references.pmid: 10601638
references.citation: J Infect Dis. 2000 Jun;181 Suppl 3:S402-10
references.pmid: 10839724
references.citation: Biopolymers. 2000;55(1):31-49
references.pmid: 10931440
references.citation: Antimicrob Agents Chemother. 2001 Jan;45(1):331-4
references.pmid: 11120991
references.citation: Infect Immun. 2002 Jan;70(1):368-79
references.pmid: 11748203
references.citation: J Antimicrob Chemother. 2002 Sep;50(3):407-10
references.pmid: 12205067
references.citation: J Antimicrob Chemother. 2002 Dec;50(6):895-902
references.pmid: 12461010
references.citation: Vaccine. 2003 Mar 7;21(11-12):1089-93
references.pmid: 12559784
references.citation: J Pept Res. 2003 May;61(5):237-42
references.pmid: 12662357
references.citation: Exp Mol Pathol. 2003 Apr;74(2):190-5
references.pmid: 12710952
references.citation: Peptides. 2003 Nov;24(11):1723-31
references.pmid: 15019203
references.citation: Infect Immun. 1987 Oct;55(10):2420-7
references.pmid: 3653985
references.citation: Infect Immun. 1989 Oct;57(10):3142-6
references.pmid: 2777377
references.citation: J Biol Chem. 1990 Nov 5;265(31):18871-4
references.pmid: 2229048
references.citation: FEBS Lett. 1993 Jul 26;327(2):231-6
references.pmid: 8335113
references.citation: Proc Natl Acad Sci U S A. 1995 Jan 3;92(1):195-9
references.pmid: 7529412
references.citation: Arch Microbiol. 1996 Mar;165(3):164-8
references.pmid: 8599533
references.citation: J Biol Chem. 1996 Nov 8;271(45):28375-81
references.pmid: 8910461